The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.
April 26th 2024
The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Treatment Decision-Making for Complex Patients With HIV: Drug Resistance, Adverse Effects, Comorbidities and Polypharmacy, and Overcoming Barriers to Equitable Care
1.5 Credits / HIV/AIDS
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence
1.5 Credits / HIV/AIDS, Infectious Disease
View More
FDA Lists New Drug Interactions for Victrelis
February 9th 2012The FDA sent out a "Drug Safety Communication" from their Division of Drug Information on February 9, 2012, listing the important new drug interactions between Victrelis (boceprevir) and ritonavir-boosted HIV protease inhibitor drugs.
Read More